Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The initial consideration for the transaction is US$ 12 million
The first of four planned modules at the new plant is expected to come online by summer 2026
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Subscribe To Our Newsletter & Stay Updated